Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
Eledon Pharmaceuticals (NASDAQ: ELDN) announced that CEO David-Alexandre C. Gros will participate in a fireside chat at the Ladenburg Thalmann Healthcare Conference on September 29, 2022, at 2:00 p.m. ET in New York City.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eledon Pharmaceuticals (NASDAQ: ELDN) announced that CEO David-Alexandre C. Gros will participate in a fireside chat at the Ladenburg Thalmann Healthcare Conference on September 29, 2022, at 2:00 p.m. ET in New York City. Interested parties can register for the webcast here. A replay will be available afterward on the company’s website.
Eledon specializes in developing treatments targeting the CD40 Ligand pathway for transplant patients and those with autoimmune diseases.
Details
News Market Reaction – ELDN
The recorded move for ELDN in the trading session of this news was -10.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that David-Alexandre C. Gros, Chief Executive Officer, will participate in a fireside chat at the Ladenburg Thalmann Healthcare Conference on Thursday, September 29, 2022 at 2:00 p.m. ET in New York City.
To register in advance for the fireside chat webcast, sign up here.
A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at https://ir.eledon.com/events-and-presentations/events.
About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)
Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.